MENU
MAY 10, 2017 11:00 AM PDT

An ongoing evaluation of our transient expression systems; Can we predict the appropriate expression system for any drug modality?

Speaker

Abstract

CHO cells are the predominant host for biotherapeutic protein expression with approximately 70% of licensed biologics manufactured in Chinese Hamster Ovary (CHO) cells.  The ability to express therapeutic candidates in CHO cells early in the drug development process is advantageous as it minimizes changes in protein quality and function when transitioning to production scale.  To address the lack of a robust and reproducible in-house transient CHO expression system, we incorporated the ExpiCHO™ transient expression system into our transient expression toolbox, joining the well-established HEK293-6E and Expi293™ systems.  With an ever-expanding array of protein formats, the next challenge is being able to strategically match a construct with an expression system.  We have utilized a diverse set of candidate proteins in an ongoing evaluation comparing material transiently produced in parallel in the HEK293-6E, ExpiCHO™ and Expi293™ systems for expression level and product quality.  We report these results and discuss their implications in how we prioritize our selection of expression systems.  Successful prioritization of an expression system for a drug modality will reduce parallel efforts and increase our throughput efficiency by reducing expression timelines


You May Also Like
MAY 10, 2017 11:00 AM PDT

An ongoing evaluation of our transient expression systems; Can we predict the appropriate expression system for any drug modality?



Loading Comments...
  • See More